ChartMill · Feb 24, 2026
Inogen Inc (NASDAQ:INGN) Stock Falls on Revenue Miss and Cautious 2026 Outlook
Inogen's narrower Q4 loss beat estimates, but a revenue miss and cautious 2026 outlook led to a sharp stock decline.
NASDAQ · INGN
Healthcare · Medical - Devices
$5.60
Up+$0.10 (+1.74%)
Updated Aug 19, 2026, 6:15 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
INGN closed at $5.60 after 21 trading sessions, down 12.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $5.70 | $5.755 | $5.57 | $5.60 | 242.83K |
| Aug 17, 2026 | $5.71 | $5.81 | $5.63 | $5.71 | 265.96K |
| Aug 14, 2026 | $5.80 | $5.82 | $5.72 | $5.75 | 204.69K |
| Aug 13, 2026 | $5.84 | $5.90 | $5.80 | $5.81 | 166.08K |
| Aug 12, 2026 | $5.90 | $5.90 | $5.80 | $5.81 | 239.49K |
| Aug 11, 2026 | $6.278 | $6.278 | $5.86 | $5.90 | 334.49K |
| Aug 10, 2026 | $6.05 | $6.29 | $5.9502 | $6.02 | 280.36K |
| Aug 7, 2026 | $5.895 | $6.26 | $5.6131 | $6.05 | 599.11K |
| Aug 6, 2026 | $6.61 | $6.715 | $6.45 | $6.49 | 283.31K |
| Aug 5, 2026 | $6.93 | $6.93 | $6.49 | $6.56 | 288.96K |
| Aug 4, 2026 | $6.70 | $6.93 | $6.69 | $6.92 | 308.14K |
| Aug 3, 2026 | $6.50 | $6.87 | $6.50 | $6.71 | 264.24K |
| Jul 31, 2026 | $6.40 | $6.46 | $6.12 | $6.45 | 282.53K |
| Jul 30, 2026 | $6.39 | $6.51 | $6.3899 | $6.42 | 124.82K |
| Jul 29, 2026 | $6.38 | $6.51 | $6.38 | $6.43 | 148.84K |
| Jul 28, 2026 | $6.33 | $6.5477 | $6.33 | $6.42 | 134.89K |
| Jul 27, 2026 | $6.24 | $6.45 | $6.24 | $6.31 | 191.64K |
| Jul 24, 2026 | $6.38 | $6.4385 | $6.13 | $6.15 | 233.4K |
| Jul 23, 2026 | $6.40 | $6.54 | $6.315 | $6.32 | 308.6K |
| Jul 22, 2026 | $6.50 | $6.55 | $6.315 | $6.51 | 216.34K |
| Jul 21, 2026 | $6.36 | $6.6089 | $6.33 | $6.43 | 146.28K |
The latest Smart Investors Daily articles mentioning INGN.
INGN research
Company profile and research snapshot.
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 7, 2026 | Freedom Broker | Buy | — |
| Jun 16, 2025 | B. Riley Securities | Buy | — |
| May 22, 2025 | Needham | Buy | — |
| May 8, 2025 | Stifel | Hold | — |
| Apr 9, 2025 | Needham | Hold | — |
No generated briefing is available yet.
ChartMill · Feb 24, 2026
Inogen's narrower Q4 loss beat estimates, but a revenue miss and cautious 2026 outlook led to a sharp stock decline.
SeekingAlpha · Feb 24, 2026
Benzinga · Feb 24, 2026
Inogen (NASDAQ:INGN) Sees Q126 Sales in line with 1Q25
Benzinga · Feb 24, 2026
Inogen (NASDAQ:INGN) sees FY2026 sales of $366.000 million-$373.000 million vs $385.250 million analyst estimate.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning INGN.